Dexcom (DXCM) Research & Development (2010 - 2026)

Dexcom (DXCM) has 17 years of Research & Development data on file, last reported at $145.3 million in Q1 2026.

• Research & Development for Q1 2026 came in at $145.3 million, changed 0.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $599.2 million (up 7.75% YoY), and the FY2025 annual result was $599.1 million, up 8.45% from the prior year.
• Research & Development declined to $145.3 million in Q1 2026 per DXCM's latest filing, from $148.2 million in the prior quarter.
• Over five years, Research & Development peaked at $157.5 million in Q3 2025 and troughed at $110.3 million in Q3 2022.
• A 5-year average of $134.5 million and a median of $136.0 million in 2024 frame the typical range for Research & Development.
• On a YoY basis, Research & Development climbed as much as 24.22% in 2022 and fell as far as 22.36% in 2022.
• A 5-year view of Research & Development shows it stood at $116.3 million in 2022, then climbed by 17.02% to $136.1 million in 2023, then increased by 2.5% to $139.5 million in 2024, then advanced by 6.24% to $148.2 million in 2025, then retreated by 1.96% to $145.3 million in 2026.
• Business Quant data shows DXCM's Research & Development at $145.3 million in Q1 2026, $148.2 million in Q4 2025, and $157.5 million in Q3 2025.